NOT-HL-21-039: Notice of NHLBI Participation in RFA-NS-21-010: "HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional)"

Notice of NHLBI Participation in RFA-NS-21-010: "HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional)"

Notice Number:

NOT-HL-21-039

Key Dates

Release Date:

October 26, 2021

Related Announcements

RFA-NS-21-010 - HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional)

Issued by

National Heart, Lung, and Blood Institute (NHLBI)

Purpose

The purpose of this Notice is to inform potential applicants that the National Heart, Lung, and Blood Institute (NHLBI) is participating, effective immediately, in RFA-NS-21-010 - "HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional)".

The following sections of RFA-NS-21-010 have been modified to highlight NHLBI's participation in this FOA:

Currently Reads:

Part 1. Overview Information

Components of Participating Organizations

National Institute of Neurological Disorders and Stroke (NINDS)
National Eye Institute (NEI)
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
National Institute of Dental and Craniofacial Research (NIDCR)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Institute on Drug Abuse (NIDA)
National Center for Complementary and Integrative Health (NCCIH)

All applications to this funding opportunity announcement should fall within the mission of the Institutes/Centers. The following NIH Offices may co-fund applications assigned to those Institutes/Centers.

Office of Research on Women's Health (ORWH)

Assistance Listing Number(s)

93.853; 93.273, 93.866,93.213; 93.867; 93.273; 93.846; 93.865; 93.279; 93.121; 93.847; 93.313

Modified to Read (changes shown in bold italics):

Part 1. Overview Information

Components of Participating Organizations

Office of Research on Women's Health (ORWH)

Assistance Listing Number(s)

93.853; 93.273, 93.866, 93.213; 93.867; 93.273; 93.846; 93.865; 93.279; 93.121; 93.847; 93.313; 93.839, 93.837, 93.838, 93.840, 93.233

Additionally, the following sections have been modified to add NHLBI-specific information and agency contacts:

Part 2. Full Text of Announcement

Section I. Funding Opportunity Description

Scope:

IC-Specific Areas of Interest

The NHLBI is interested in preclinical optimization and development of safe, effective, and non-addictive small molecule and biologic therapeutics for pain conditions within the mission of NHLBI. Topics of special interest include, but are not limited to the pain associated with blood diseases such as sickle cell disease, hemophilia, and deep venous thrombosis and heart diseases and lung diseases such as chronic obstructive pulmonary disease, cystic fibrosis related arthritis, lung transplantation where opioid dependency can be an issue, chronic pain from tube thoracostomy, severe chronic cough, and pain associated with mechanical ventilation in critical care patients.

Section VII. Agency Contacts

Scientific/Research Contact(s)

Asif Rizwan, PhD
National Heart, Lung and Blood Institute (NHLBI)
Telephone: 301-435-0070
E-mail: [email protected]

Financial/Grants Management Contact(s)

Nina Hall
National Heart, Lung and Blood Institute (NHLBI)
Telephone: 301-827-2393
E-mail: [email protected]

Inquiries

Please direct all inquiries to:

Asif Rizwan, PhD
National Heart, Lung and Blood Institute (NHLBI)
Telephone: 301-435-0070
E-mail: [email protected]